Aquestive(AQST)
搜索文档
Aquestive(AQST) - 2019 Q3 - Earnings Call Transcript
2019-11-09 12:06
Aquestive Therapeutics, Inc. (NASDAQ:AQST) Q3 2019 Earnings Conference Call November 6, 2019 8:00 AM ET Company Participants Stephanie Carrington - Westwicke Investor Relations Keith Kendall - Chief Executive Officer John Maxwell - Chief Financial Officer Ken Marshall - Chief Commercial Officer Dan Barber - Senior Vice President & Chief Operating Officer Conference Call Participants Rafay Sardar - BMO Capital Markets Liana Moussatos - Wedbush Securities Jason Butler - JMP Securities Thomas Flaten - Lake Str ...
Aquestive(AQST) - 2019 Q3 - Quarterly Report
2019-11-06 06:28
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Title of each class Trading Symbol(s) Name of each exchange on which registered Common Stock, par value $0.001 per share AQST NASDAQ Global Market FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2019 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from _____ t ...
Aquestive(AQST) - 2019 Q2 - Earnings Call Transcript
2019-08-08 09:30
Aquestive Therapeutics, Inc. (NASDAQ:AQST) Q2 2019 Earnings Conference Call August 7, 2019 8:00 AM ET Company Participants Lauren Walrath - Head, Corporate Marketing and Communications Keith Kendall - Chief Executive Officer John Maxwell - Chief Financial Officer Gary Slatko - Senior Vice President, Chief Medical Officer Ken Marshall - Chief Commercial Officer Dan Barber - Senior Vice President & Chief Operating Officer Conference Call Participants Ashley Ryu - RBC Capital Markets Liana Moussatos - Wedbush ...
Aquestive(AQST) - 2019 Q2 - Quarterly Report
2019-08-07 05:03
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2019 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from _____ to _____ Commission File Number: 001-38599 Aquestive Therapeutics, Inc. (Exact Name of Registrant as Specified in its Charter) Delaware 30 Technology Dri ...
Aquestive(AQST) - 2019 Q1 - Earnings Call Transcript
2019-05-11 20:01
Aquestive Therapeutics, Inc. (NASDAQ:AQST) Q1 2019 Earnings Conference Call May 8, 2019 8:00 AM ET Company Participants Lauren Walrath - Head, Corporate Marketing and Communications Keith Kendall - Chief Executive Officer Ken Marshall - Chief Commercial Officer Daniel Barber - Chief Strategy and Development Officer John Maxwell - Chief Financial Officer Conference Call Participants Randall Stanicky - RBC Capital Markets Liana Moussatos - Wedbush Securities Thomas Flaten - Lake Street Capital Ram Selvaraju - ...
Aquestive(AQST) - 2019 Q1 - Quarterly Report
2019-05-09 01:31
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2019 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from _____ to _____ Commission File Number: 001-38599 Aquestive Therapeutics, Inc. (Exact Name of Registrant as Specified in its Charter) Delaware 30 Technology Dr ...